We are live on ! Find out more

905 hedge funds and large institutions have $18.5B invested in Biogen in 2025 Q3 according to their latest regulatory filings, with 122 funds opening new positions, 322 increasing their positions, 269 reducing their positions, and 74 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more call options, than puts

Call options by funds: $573M | Put options by funds: $316M

65% more first-time investments, than exits

New positions opened: 122 | Existing positions closed: 74

20% more repeat investments, than reductions

Existing positions increased: 322 | Existing positions reduced: 269

13% more capital invested

Capital invested by funds: $16.4B → $18.5B (+$2.11B)

5% more funds holding

Funds holding: 866905 (+39)

0.76% more ownership

Funds ownership: 88.8%89.57% (+0.76%)

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

Holders
905
Holders Change
+39
Holders Change %
+4.5%
% of All Funds
11.88%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.04%
New
122
Increased
322
Reduced
269
Closed
74
Calls
$573M
Puts
$316M
Net Calls
+$257M
Net Calls Change
+$209M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.42B -$191K -1,416 -0%
Primecap Management
2
Primecap Management
California
$2.09B -$115M -847,425 -5%
BlackRock
3
BlackRock
New York
$2.07B +$163M +1,208,486 +9%
State Street
4
State Street
Massachusetts
$1.03B -$20.1M -149,058 -2%
Wellington Management Group
5
Wellington Management Group
Massachusetts
$595M -$74.6M -551,916 -12%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$568M +$20.4M +150,631 +4%
Point72 Asset Management
7
Point72 Asset Management
Connecticut
$543M +$5.57M +41,174 +1%
Invesco
8
Invesco
Georgia
$339M +$13.2M +98,001 +4%
Morgan Stanley
9
Morgan Stanley
New York
$315M +$39.9M +295,325 +15%
AQR Capital Management
10
AQR Capital Management
Connecticut
$249M +$56.6M +418,776 +31%
Legal & General Group
11
Legal & General Group
United Kingdom
$223M +$19.8M +146,583 +10%
Northern Trust
12
Northern Trust
Illinois
$210M -$5.09M -37,648 -2%
Pacer Advisors
13
Pacer Advisors
Pennsylvania
$203M +$17.7M +131,258 +10%
UBS AM
14
UBS AM
Illinois
$202M -$41.1M -304,001 -17%
Barclays
15
Barclays
United Kingdom
$190M +$75.9M +561,769 +70%
Fidelity Investments
16
Fidelity Investments
Massachusetts
$180M -$52.2M -386,460 -23%
JP Morgan Chase
17
JP Morgan Chase
New York
$178M +$35.9M +265,848 +27%
Balyasny Asset Management
18
Balyasny Asset Management
Illinois
$173M +$54.4M +402,244 +48%
Deutsche Bank
19
Deutsche Bank
Germany
$172M +$14.6M +108,124 +10%
Bank of America
20
Bank of America
North Carolina
$171M +$21.2M +156,627 +15%
Charles Schwab
21
Charles Schwab
California
$157M +$6.43M +47,592 +4%
Millennium Management
22
Millennium Management
New York
$156M +$58.9M +435,688 +64%
T. Rowe Price Investment Management
23
T. Rowe Price Investment Management
Maryland
$150M -$44.2M -326,994 -23%
VanEck Associates
24
VanEck Associates
New York
$149M -$1.07M -7,880 -0.7%
Goldman Sachs
25
Goldman Sachs
New York
$149M +$53.1M +392,734 +59%

BIIB Hedge Fund Activity: Q3 2025 in Review

905 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2025, worth a combined $18.5B — up 13% from $16.4B a quarter earlier.

Buyers outnumbered sellers: 122 funds opened new BIIB positions and 74 closed out — a net gain of 48 holders — while 322 added to existing stakes and 269 trimmed.

The largest buyer was BlackRock, adding an estimated $163M. The largest seller was D.E. Shaw & Co, cutting an estimated $120M.

  • 905 institutional investors held Biogen (BIIB) as of Q3 2025, up from 866 in Q2 2025.
  • Funds reported $18.5B of Biogen stock for Q3 2025, up 13% quarter-over-quarter.
  • 122 funds opened new Biogen positions in Q3 2025 and 74 closed out, a net change of +48 holders.
  • The largest Biogen buyer in Q3 2025 was BlackRock, an estimated $163M added.
  • The largest Biogen seller in Q3 2025 was D.E. Shaw & Co, an estimated $120M sold.

Based on aggregated 13F filings for Q3 2025.